Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01907802 · ClinicalTrials.gov registry record · Phase 1
Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01907802: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01907802 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01907802, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of dabrafenib in treating patients with solid tumors and kidney or liver dysfunction. Dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
Overall toxicity incidence as well as toxicity profiles by dose level and patient will be explored and summarized. Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Dabrafenib
- OTHER Pharmacological Study
- OTHER Pharmacogenomic Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-08-23 |
| Est. Completion | 2015-12-16 |
| Phase | Phase 1 |
Why NCT01907802 stopped before completion
NCT01907802 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01907802 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01907802 about?
NCT01907802 is a clinical study titled "Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction". This phase I trial studies the side effects and best dose of dabrafenib in treating patients with solid tumors and kidney or liver dysfunction. Dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01907802?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2013-08-23. Estimated completion is 2015-12-16.
What interventions are being tested in trial NCT01907802?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Dabrafenib (DRUG), Pharmacological Study (OTHER), Pharmacogenomic Study (OTHER).
Who is sponsoring clinical trial NCT01907802?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01907802's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI